Clinical Trials in Puyang, Henan
13 recruiting
Showing 1–13 of 13 trials
Recruiting
Phase 3
Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
Intracerebral Hemorrhage
Beijing Tiantan Hospital1,192 enrolled41 locationsNCT07338175
Recruiting
Phase 2
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
Pulmonary Disease, Chronic Obstructive
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.195 enrolled29 locationsNCT07252908
Recruiting
Not Applicable
Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
Coronary Artery Disease (CAD)Chronic Total Occlusions of Coronary Arterieschronic total occlusion (CTO)
The First Affiliated Hospital of Zhengzhou University200 enrolled18 locationsNCT07463664
Recruiting
Phase 2
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
Toll Biotech Co. Ltd. (Beijing)24 enrolled6 locationsNCT07408024
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 3
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.560 enrolled68 locationsNCT07284134
Recruiting
Phase 3
Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.
Acute Ischemic Stroke
CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.890 enrolled1 locationNCT07201688
Recruiting
Phase 3
A Two-Part, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
Hyperkalemia
Waterstone Pharmaceutical (Wuhan) Co., LTD.420 enrolled50 locationsNCT07251309
Recruiting
Phase 2
A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.204 enrolled39 locationsNCT06767800
Recruiting
Phase 3
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Ischemic Stroke, Acute
Beijing Tiantan Hospital1,380 enrolled82 locationsNCT06157502
Recruiting
Phase 3
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.642 enrolled25 locationsNCT07003074
Recruiting
Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.80 enrolled30 locationsNCT06566586
Recruiting
Phase 2
Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)
Non Alcoholic Steatohepatitis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.120 enrolled53 locationsNCT06569524